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Abstract: Acute cardiovascular disease after community-acquired pneumonia is a well-accepted
complication for which definitive treatment strategies are lacking. These complications share some
common features but have distinct diagnostic and treatment approaches. We therefore undertook
an updated systematic review and meta-analysis of observational studies reporting the incidence of
overall complications, acute coronary syndromes, new or worsening heart failure, new or worsening
arrhythmias and acute stroke, as well as short-term mortality outcomes. To set a framework for future
research, we further included a holistic review of the interplay between the two conditions. From 1984
to 2019, thirty-nine studies were accrued, involving 92,188 patients, divided by setting (inpatients
versus outpatients) and clinical severity (low risk versus high risk). Overall cardiac complications
occurred in 13.9% (95% confidence interval (CI) 9.6–18.9), acute coronary syndromes in 4.5% (95% CI
2.9–6.5), heart failure in 9.2% (95% CI 6.7–12.2), arrhythmias in 7.2% (95% CI 5.6–9.0) and stroke in
0.71% (95% CI 0.1–3.9) of pooled inpatients. During this period, meta-regression analysis suggests
that the incidence of overall and individual cardiac complications is decreasing. After adjusting for
confounders, cardiovascular events taking place after community-acquired pneumonia independently
increase the risk for short-term mortality (range of odds-ratio: 1.39–5.49). These findings highlight
the need for effective, large trial based, preventive and therapeutic interventions in this important
patient population.
Keywords: pneumonia; community-acquired; cardiovascular complications; acute coronary
syndromes; heart failure; arrhythmias; stroke
1. Introduction
Community-acquired pneumonia (CAP) and cardiovascular (CV) disease are two major public
health issues. CAP alone results in 1.7 million hospital admissions and almost 50,000 deaths every year
in the USA [1,2], with a similar adjusted incidence observed in Europe [3,4]. In developed countries,
CV disease is the leading cause of morbidity and mortality. Together, these conditions weigh heavily
on national health systems and efforts to mitigate their global burden should be a priority for policy
makers [5].
Although seemingly unrelated beforehand, the interplay between CAP and acute CV events
has been elucidated in the last decades [6]. Myocardial infarction, heart failure, arrhythmias and
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stroke were witnessed to increase following a CAP episode [7]. The risk is maximal during the
acute phase but persists in time after the infection has abated [8]. Moreover, a higher likelihood
of a poorer outcome in a patient with CAP complicated by a CV event exists when compared to
one with an uncomplicated course [7]. At the population level, the practical implications of such
an association are immense. The widespread use of influenza and pneumococcal vaccination is an
attractive option. When considering treatment possibilities, drugs with proven efficacy in the CV arena
could theoretically be initiated to modulate outcomes, both acutely but also in the context of long-term
CV prevention. Definite evidence-based guidance on how to perform these interventions at a patient
level is, however, lacking.
In this article, we provide a broadened description of the current evidence associating CAP and
acute CV disease. From bench to bedside, we begin with mechanistic links of the pathophysiologic
repercussion of CAP on the cardiovascular system, proceed to an updated systematic review of and
meta-analysis of observational clinical studies and end with the impact of potential interventions and
future avenues of research.
2. Materials and Methods
2.1. Search Strategy
We searched Medline from inception to 1 November 2019 for articles in English, French, Spanish,
and Portuguese languages evaluating the incidence of subsequent CV events after a first CAP
episode (community-acquired pneumonia” AND (“complications” OR “acute coronary syndromes”
OR “myocardial infarction” OR “heart failure” OR “arrhythmia” OR “atrial fibrillation” OR “stroke”).
To ensure the completeness of our review, we also retrieved previously published reviews on the
subject and scanned their references for any additional missed publications in the primary search.
2.2. Population and Outcomes
We restricted our search to adult non-immunocompromised patients with clinical and radiological
evidence of CAP (as a means to improve specificity) for whom outcomes were explicitly reported in the
methods section. Consecutive enrolment of patients and the quantification of CV events in the entire
cohort were also prerequisites for inclusion. Studies focusing on nosocomial or health care–associated
pneumonia, antibiotic efficacy trials (due to selection bias) and articles dealing primarily with pediatric
patients or patients infected with the human immunodeficiency virus were excluded.
If assessed, independent predictors for CV complications after CAP were collected and tabulated.
To minimize the influence of patient heterogeneity in the estimation of effect sizes, we stratified patients
according to treatment setting and clinical severity, when available. Patients initially treated in an
ambulatory setting were defined as outpatients while patients admitted to a hospital on presentation
were considered as inpatients. High risk patients were defined as having a pneumonia severity index
(PSI) class IV or V or and/or requiring admission to the intensive care unit (ICU). Cardiovascular
events were categorized as overall cardiac complications, acute coronary syndromes, new or worsening
heart failure, and new or worsened arrhythmia and stroke. We collected data on all-cause mortality
occurring either during hospital admission on during the first 30 to 90 days.
2.3. Study Selection, Data Extraction and Synthesis
After the initial search, the first author extracted all abstracts, excluded irrelevant studies and if
deemed adequate, proceeded to full-text reading and data tabulation. Study flowchart is depicted in
Figure 1. The methodologic quality of available studies was graded according to Preferred Reporting
Items for Systematic reviews and Meta-analyses (PRISMA) guidelines (Supplementary Table S1).
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2.4. Statistical Analysis
In contrast to a traditional meta-analysis aiming to describe an effect size related to a therapeutic
intervention, a meta-analysis of proportions has the goal of obtaining a more precise estimate of the
overall proportion for a certain case or event [9]. In order to achieve this, raw proportional data
need to be conformed to the normal distribution by employing one of several validated statistical
approaches. We chose Freeman and Tukey’s double-arcsine transformation, a method which stabilizes
study variance and reduces the probability of inaccurate weighting of each study when the inverse
of the variance of the transformed proportion is used as a study weight [10]. To further minimize
population differences between studies, patient cohorts were divided by event category, setting, and
clinical severity before estimating pooled event rates using a random-effects model.
We anticipated that the identification of more studies spanning the eight-year time frame after
the last published systematic review would justify an analysis by year of publication. Therefore, a
meta-regression using year of publication as a moderator variable was undertaken. To predict the
effect of a hypothesized moderator, a weighted linear regression model was performed, in which the
effect sizes (i.e., transformed proportions of CV events) are regressed onto the moderator, and a linear
equation obtained. Finally, we assessed for publication bias by funnel plot inspection [11] and formally
by Egger’s test [12]. In a funnel plot, each study is inscribed around the summary effect size (a vertical
line) bounded by two converging slopes defining the 95% confidence interval around it. Imprecision is
decrementally displayed on the y-axis and is zero at the triangle vertex. Absence of bias would result
in a perfectly symmetrical plot. All analysis were performed using R (version 3.6.1, Vienna, Austria).
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3. Results
3.1. Basic Science and Clinical Insights Associating CAP to CV Events
3.1.1. Coronary Arteries and Myocardial Infarction
Theoretically, three different mechanisms prompted by pneumonia can contribute to a coronary
event: (1) plaque rupture or fissuring leading to superimposed thrombus formation and cardiac
troponin rise and/or fall, corresponding to type 1 myocardial infarction (MI); (2) type 2 MI, due to an
imbalance between oxygen delivery and consumption in the myocardium, together with ischemic
symptoms, especially if fixed stenoses are present, and (3) “myocardial injury”, when a troponin
leak is detected without evidence of ischemia [13]. The most accepted and important pathway
involves inflammation driven plaque instability [14]. By experimentally inducing sepsis in animal
models, investigators have found post-mortem pathologic proof of atheromata growth and vascular
inflammation. In mice fed with an atherogenic diet and subsequently developing provoked secondary
fecal peritonitis, Kaynar et al. found increased abdominal aorta atheroma size, plaque neutrophil
count and circulating proinflammatory cytokines versus a sham procedure, all persisting five months
after the index intervention [15]. In humans, similarities are quite striking. In a post-mortem study,
Mauriello et al. performed a detailed histologic analysis of coronary segments of sixteen patients who
died after acute MI and compared them with controls who died of non-cardiac causes and had either
stable angina or no CAD suspicion [16]. Significantly increased inflammatory infiltrates (macrophage
and T-lymphocyte) were noticed not only in the culprit lesion but also in non-culprit vulnerable plaques
and stable plaques in MI patients, suggesting underlying inflammation of the entire coronary tree even
without sepsis. In another small sized study, fourteen patients who died from systemic infection (six of
which with either upper or lower respiratory tract infection) were found to have more leucocytes in
both plaque and adventitia than controls [17]. Inflammation that persists after the acute infectious
episode could be causally linked increased mortality witnessed after hospital discharge following
CAP [6].
Other proposed pathophysiologic pathways include hypercoagulability and hampered vascular
tone. A significant proportion of pneumonia patients exhibited increased levels of coagulation markers
in a study by Milbrandt et al, which persisted up to a week after hospital admission and were associated
with increased mortality [18]. Although coronary perfusion is preserved or even increased in human
septic shock [19], vasomotor disturbances resulting from changes in vasoactive mediators and capable
of compromising myocardial oxygen delivery have been reported in animal [20] studies and could
play a role in severe Gram positive infections.
3.1.2. Myocardium and Heart Failure
Direct myocardial involvement by pathogens has been shown for viral and bacterial myocarditis
caused mainly by influenza virus, adenovirus, respiratory syncytial virus and enterovirus but
also bacteria including Streptococcus pneumoniae, Chlamydophila pneumoniae, Mycoplasma pneumoniae,
Staphylococcus aureus and Legionella spp. [7]. Molecular studies have further suggested that up to a third
of CAP cases in adults result from viral infection [7]. Kotaka et al. demonstrated that influenza virus
inoculation in a murine model led to cytotoxic effect in cardiomyocytes and coronary thrombosis [21].
In the human heart, necropsy studies have similarly revealed edema, sarcomeric disarray and viral
particle isolation from fatal influenza infection. Following invasive pneumococcal disease, Brown
et al. disclosed for the first time how Streptococcus pneumoniae translocates into the myocardium of
primates and patients who succumbed to CAP [22]. In their study, microlesions containing bacteria
were described inside cardiomyocytes, which if treated with antibiotics led to local inflammation
and scarring. The authors speculate that these foci may generate future myocardial dysfunction or
cardiac arrhythmias.
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3.1.3. Cardiac Rhythm Disturbances
Atrial fibrillation is the most common sustained arrhythmia encountered in clinical practice [23].
Known transient risk factors include fever, hypoxia and hemodynamic disturbances, all of which can
be triggered by infections including pneumonia [24]. An increased incidence in AF as well as other
specified arrhythmias following CAP is a phenomenon well described in the literature. In a study
conducted in critically ill patients, sepsis and acute respiratory failure were the most powerful predictors
of AF onset [25]. Proposed mechanisms include direct toxic effect on the cardiac electric system,
augmented loading imposed on cardiomyocytes, inflammation, sympathetic hyperactivity, ischemia
and pharmacological agents, including antibiotics. AF occurrence is associated with worse short
and long term outcomes in patients with infections [26,27], directly influencing patient management,
namely the decision to initiate anticoagulation, and conditioning rhythm or rate control strategies.
3.2. Clinical Studies of Short Term Incident Acute CV Disease after CAP
We found 39 studies (Table 1, see also Supplementary Table S2 for detailed study description)
reporting the incidence of CV events following CAP. Retrieved studies spanned a thirty-five-year
period and included mostly North American patients. The mean weighted age of patients was 72 ± 11
years and most were male (79%).
Table 1. Characteristics of included studies.
- Year Country Study Type Setting n
CV
Events a
(%)
ACS b
(%)
Heart
Failure
(%)
Stroke c
(%)
Arrhythmias d
(%)
Allen et al.
[28] 1984 Zambia
Retrospective
single center Inpatients 502 - - - - 0.40
Esposito
et al. [29] 1984 USA
Prospective
single center Inpatients 38 - - 7.9 - -
Marrie
et al. [30] 1989 Canada
Prospective
single center Inpatients 583 - - 11 - -
Ortqvist
et al. [31] 1990 Sweden
Prospective,
single center Inpatients 277 13 - - - -
Venkatesan
et al. [32] 1990 UK
Prospective
single center Inpatients 73 - - - - 11
Fine et al.
[33] 1990 USA
Prospective
single center
Low-risk e
inpatients
Outpatients
170 - 0.6 - - 0.6
Woodhead
et al. [34] 1992 UK
Retrospective
multicenter
High-risk f
inpatients
72 - - - - 23
Leroy et al.
[35] 1995 France
Retrospective
single center
High-risk f
inpatients
299 2.3 - - - -
Janssens
et al. [36] 1995 Switzerland
Prospective,
single center Inpatients 99 - - 33 - -
Musher
et al. [37] 2000 USA
Prospective
single center Inpatients 100 - - 4.0 - -
Férnandez-
Sabé et al.
[38]
2003 Spain Prospectivesingle center Inpatients 1474 - - 7.2 - -
Fine et al.
[39] 2003 USA
Prospective
multicenter Inpatients 608 22 - - - -
Martínez-
Moragón
et al. [40]
2004 Spain Prospectivesingle-center Inpatients 91 5.0 - - - -
Menéndez
et al. [41] 2004 Spain
Prospective
multicenter
Low-risk e
inpatients 1424 - - 8.7 - -
Querol-
Ribelles
et al. [42]
2005 Spain Prospectivesingle-center
Low-risk e
inpatients 459 - - 8.6 - -
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Table 1. Cont.
- Year Country Study Type Setting n
CV
Events a
(%)
ACS b
(%)
Heart
Failure
(%)
Stroke c
(%)
Arrhythmias d
(%)
Díaz et al.
[43] 2005 Chile
Prospective
Single-center
High-risk f
inpatients
113 - - 24 - 15
Marrie
et al. [44] 2005 Canada
Prospective
single center
Low-risk e
inpatients 586 - 0.3 1.4 - -
McAlister
et al. [45] 2005 Canada
Prospective
multicenter
Low-risk e
inpatients 2471 5.9 - - - -
O’Meara
et al. [46] 2005 USA
Prospective
multicenter Inpatients 582 24 - - - -
Musher
et al. [47] 2007 USA
Retrospective
single-center Inpatients
g 170 19 7 15 - 6
Becker
et al. [48] 2007 Canada
Retrospective
multicenter Inpatients 391 17 8 12 - 3
Ramirez
et al. [49] 2008 Spain
Retrospective
single-center Inpatients 500 - 5.8 - - -
Cabré et al.
[50] 2008 Spain
Prospective
single-center Inpatients 117 - 0.9 12 - 4.4
Corrales-
Medina
et al. [51]
2009 USA Retrospectivesingle-center Inpatients 206 - 11 - - -
Mandal
et al. [52] 2011 Scotland
Retrospective
multicenter Inpatients 5034 - 5.0 - 2.2 9.3
Perry et al.
[53] 2011 USA
Retrospective
multicenter Inpatients 50119 - 2.3 9.1 0.1 8.4
Corrales-
Medina
et al. [54]
2012 USA andCanada
Prospective
multicenter
Inpatients
Outpatients
1343
944
27
2.1
3.6
0
67
65 -
22
35
Viasus
et al. [55] 2013 Spain
Prospective
single center
Low-risk
inpatients
High-risk
inpatients f
1621h
2300
3.0
11.6 0.76 3.0 - 5.1
Griffin
et al. [56] 2013
13
countries
Retrospective
multicenter Inpatients 3068 14 1.3 2.1 - 3.6
Aliberti
et al. [57] 2015
Italy,
Switzerland
Retrospective
multicenter Inpatients 905 - 2.3 3.7 1.1 19
Cangemi
et al. [58] 2015 Italy
Prospective,
single center Inpatients 301 18 11 - - 10
Corrales-
Medina
et al. [59]
2015 USA Retrospectivemulticenter Inpatients 508 11 - - - -
Corrales-
Medina
et al. [59]
2015 USA Retrospectivemulticenter Inpatients 426 0.90 - - - -
Chen et al.
[60] 2015 Taiwan
Single-center
retrospective Inpatients 746 - 2.3 - - -
Violi et al.
[61] 2017
Italy,
Canada
Prospective
multicenter
Low-risk
inpatients
High-risk
inpatients f
355 h
827
12
41 8.4 24 0.1 9.2
Eurich
et al. [62] 2017 Canada
Prospective
multicenter
Inpatients
Outpatients 4988 - - 12 - -
Cilli et al.
[63] 2018 Turkey
Retrospective
multicenter
High-risk f
inpatients
373 15 0.54 2.9 - 12
Postma
et al. [64] 2019 Netherlands
Retrospective
multicenter Inpatients 2107 7.9 0.7 4.8 - 2.5
Pieralli
et al. [65] 2019 Italy
Retrospective
single-center Inpatients 468 - - - - 10.3
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Table 1. Cont.
- Year Country Study Type Setting n
CV
Events a
(%)
ACS b
(%)
Heart
Failure
(%)
Stroke c
(%)
Arrhythmias d
(%)
Cangemi
et al. [66] 2019 Italy
Prospective
single center Inpatients 545 - - - - 9.5
a Cardiovascular (CV) events: congestive heart failure, atrial fibrillation, severe angina or myocardial infarction
or stroke [31]; acute coronary or ventricular insufficiency [35]; cardiovascular complications likely to necessitate
continued hospitalization [39]; cardiac complications without further specification [40]; acute coronary syndrome
and/or heart failure [45]; myocardial infarction, angina pectoris, revascularization by angioplasty/coronary artery
bypass graft (CABG) or death secondary to coronary heart disease, cerebrovascular accident, congestive heart
insufficiency or claudication [46]; myocardial infarction, atrial fibrillation or ventricular tachycardia or incident
heart failure [47]; myocardial infarction, atrial fibrillation, congestive heart failure or stroke [48]; new or worsening
heart failure, new or worsening arrhythmias or myocardial infarction [54]; new-onset or worsening cardiac
arrhythmias, new-onset or worsening congestive heart failure or myocardial infarction [55]; acute pulmonary
edema, new onset cardiac arrhythmia, exacerbation of a preexisting arrhythmia, or myocardial infarction [56];
acute myocardial infarction, acute cardiogenic pulmonary edema, new arrhythmia, acute worsening of a long-term
arrhythmia, cerebrovascular accident or pulmonary embolism [57];cardiovascular death, non-fatal myocardial
infarction or stroke [58]; non-ST elevation myocardial infarction or ST elevation myocardial infarction, stroke,
new episode of atrial fibrillation or deep venous thrombosis and/or pulmonary embolism, new or worsening
HF or cardiovascular death [61] new onset or worsening arrhythmia, new onset or worsening heart failure or
myocardial infarction [63]: new or worsening arrhythmia, heart failure or myocardial ischemia [64]. b Acute coronary
syndromes (ACS): myocardial infarction [33,37,39,47–49,53–58,60,61,63,64]; unstable angina [44]; acute coronary
syndrome [50,51]; acute coronary syndrome or ST segment elevation myocardial infarction [52]. c Stroke: new-onset
neurological deficit [53]; unspecified stroke [52,61]; cerebrovascular accident [57]. d Arrhythmias: incident atrial
fibrillation [28,32,33,48–50,52–58,61,64–66]; cardiac dysrhythmias/arrhythmias [34,43]; atrial flutter or fibrillation,
and ventricular tachycardia, but excluding terminal arrhythmias [47]. e Inpatients without severe vital signs or
metabolic abnormalities, altered mental status, suppurative complications or coexisting medical conditions requiring
hospitalization [33]; inpatients who survived the first 48 h of hospitalization [41], inpatients not initially admitted to
the intensive care unit [42,45]; inpatients with pneumonia severity index (PSI) risk classes I–II [44]. f Inpatients
admitted to the intensive care unit (ICU). g For ACS, patients from Musher et al. (2007) [47] were included in
Corrales-Medina et al. (2009) [51]. h Data available for low-risk or high-risk patients if overall cardiac events
are considered.
3.2.1. Overall Cardiac Complications
Twelve studies provided data on inpatients [31,39,40,46–48,54,56,58,59,64], four on low-risk
inpatients [45,55,57,61] and five on high-risk inpatients [35,55,57,61,63]. Pooled event rates were 13.9%
(95% confidence interval (CI) 9.6–18.9), 5.7% (95% CI 3.1–9.0) and 15.6% (95% CI 6.1–28.4), respectively
(Figure 2).
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3.2.2. Acute Coronary Syndromes
Thirteen studies reported at on inpatients [4 , , , 1,64], two on low-risk patients [44,57]
and high-risk [57,63] patients and one on outpatients [54]. Pooled event rates were 4.5% (95% CI
2.9–6.5), 0.2 (95% CI 0–0.7), 1.6 (95% CI 0.1–4.9), and 0.9 (95% CI 0.5–1.8), respectively (Figure 3).
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3.2.3. Heart Failure
Sixteen studies included inpatients [29,30,36–38,47,48,50,53–57,61,62,64], three focused on low-risk
patients [41,42,44], two focused on high-risk patients [43,63], and two on outpatients [54,62]. Pooled
event rates were 9.2% (95% CI 6.7–12.2), 5.6% (95% CI 1.5–11.9), 11.1% (95% CI% 0–39), and 1.0% (95%
CI 0.6–1.6), respectively (Figure 4).
J. Clin. Med. 2020, 9, x FOR PEER REVIEW 9 of 23 
(C)
(D) 
Figure 3. Forest plots of incident acute corona y syndromes (ACS) after comm nity-acq ired 
pneumonia. (A) Inpatients (B) Low-risk inpatients (C) High-risk inpatients (D) Outpatients. CI: 
confidence interval. 
3.2.3. Heart Failure
Sixteen studies incl d  inpatients [29,30,36–38,47,48,50,53–57,61,62,64], thre  focused on low-
risk patients [41,42,44], two focused on high-risk patients [43,63], and two on outpatie ts [54,62]. 
Pooled event rates were 9.2% (95% CI 6.7–12.2), 5.6% (95% CI 1.5–11.9), 11.1% (95% CI% 0–39), and
1.0% (95% CI 0.6–1.6), respectively (Figure 4). 
(A) 
(B)
Figure 4. Cont.
J. Clin. Med. 2020, 9, 414 10 of 23
J. Clin. Med. 2020, 9, x FOR PEER REVIEW 10 of 23 
(C) 
(D) 
Figure 4. Forest plots of incident heart failure after community-acquired pneumonia. (A) Inpatients 
(B) Low-risk inpatients (C) High-risk patients (D) Outpatients. CI: confidence interval.
3.2.4. Arrhythmias 
Incident arrhythmias were mentioned in twenty studies. Seventeen studies analysed inpatients 
[28,32,34,47,48,50,52–58,61,64–66], two focused on high-risk inpatients [43,63] and one on outpatients 
[54]. Pooled event rates were 7.2% (95% CI 5.6–9.0), 12.7% (95% CI 9.8–15.8), and 0.7% (95% CI 0.3–1.5), 
respectively (Figure 5). 
(A) 
(B)
Figure 4. Forest plots of incident heart failure after com unity-acquired pneumonia. (A) Inpatients (B)
Low-risk inpatients (C) High-risk patients (D) Outpatients. CI: confidence interval.
3.2.4. Arrhythmias
Incident arrhythmias wer mentioned in twenty studies. Seventeen studies analysed inpatients [28,
32,34,47,48,50,52–58,61,64–66], two focused on high-risk inpatients [43,6 ] and one on outpatients [54].
Pooled event rates were 7.2% (95% CI 5.6–9.0), 12.7% (95% CI 9.8–15.8), and 0.7% (95% CI 0.3–1.5),
respectively (Figure 5).
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3.2.5. Stroke
New-onset stroke following CAP was reported in four studies [52,57,61,63], all on inpatients.
Po led event rate was 1.7% (95% CI 1.0–2.6; Figure 6).
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3.3. Risk Factors and Impact of Cardiac Complications on CAP Outcomes
Risk factors for the occurrence of CV events were reported in thirteen studies [51–58,61,63–66].
After adjustment for covariates, several clinical, microbiologic, laboratory, and imaging features were
found to be independent predictors of an adverse CV event (Table 2).
Table 2. Included studies presenting independent predictors of cardiovascular (CV) events after
community-acquired pneumonia (CAP).
Author Year n with Event Outcome Independent Predictors
Corrales-Medina et al. [51] 2009 206 ACS AgeCongestive heart failure
Mandal et al. [52] 2011
252 ACS
Age ≥ 65
Previous MI
COPD
Chronic kidney disease
468 Arrhythmias
Age
Previous MI
Diabetes
111 Stroke Prior strokeCOPD
Perry et al. [53] 2011
2002 CHF
Age
Admission to ICU
Previous MI
COPD Diabetes
Chronic kidney disease
Cancer
2732 Arrhythmias AgeAdmission to ICU
Corrales-Medina et al. [54] 2012 378 Overall cardiaccomplications
Age
Nursing home
Hypertension
Previous CAD
Previous arrhythmias
Previous CHF
RR ≥ 30/min
pH < 7.35
BUN ≥ 30 mg/dL
Sodium < 130 mmol/L
Hematocrit < 30%
Pleural effusion
Inpatient
Viasus et al. [55] 2013 315 Overall cardiaccomplications
Age ≥ 65
Chronic heart disease
Septic shock
Tachycardia
Albumin < 3 g/dL
Multilobar pneumonia
Streptococcal pneumonia
Griffin et al. [56] 2013 376 Overall cardiaccomplications
Hyperlipidemia
Statin therapy 1
Staphylococcus aureus
Klebsiella pneumoniae
PSI
Aliberti et al. [57] 2015 21 ACS
Female sex
Severe sepsis
Liver disease
Cangemi et al. [58] 2015 55 Overall cardiaccomplications
Age
Hypertension
Diabetes
Baseline troponin
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Table 2. Cont.
Author Year n with Event Outcome Independent Predictors
Violi et al. [61] 2017 308 Overall cardiaccomplications
Age
CHF
PSI
Cilli et al. [63] 2018 56 Overall cardiaccomplications
Age
Hypoalbuminemia
Diuretic
Vasopressor
Haloperidol
Postma et al. [64] 2019 2107 Overall cardiaccomplications Erythromycin use
Pieralli et al. [65] 2019 468 Atrial fibrillation CURB-65 > 2CHA2DS2-VASc > 3
Cangemi et al. [66] 2019 545 Atrial fibrillation
Prior paroxysmal AF,
Enlarged LAAi
Left ventricular hypertrophy
1 Protective effect. ACS: acute coronary syndrome; AF: atrial fibrillation; BUN: blood urea nitrogen; CAD: coronary
artery disease; CHA2DS2-VASc: congestive heart failure, hypertension, age-doubled, diabetes, stroke-doubled,
vascular disease, age, sex-category; CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease;
CURB-65: confusion, urea, respiratory rate, blood urea nitrogen, age > 65; ICU: intensive care unit; LAAi (left atrial
area index); MI: myocardial infarction; PSI: pneumonia severity index; RR: respiratory rate.
Seven studies evaluated whether CV events were independently associated with mortality in
CAP patients [52,54,55,57,58,61,63]. Multivariate analysis and propensity score matching were used to
correct for confounders when assessing the impact of composite and individual CV events. Both overall
and individual cardiac complications were associated with increased mortality after CAP (Table 3).
Table 3. Association of CV events and mortality after CAP.
Study Year Event Mortality Measure of Risk
Mandal et al. [52] 2001
Stroke
90-day
OR 1.79 (1.51–2.12), p < 0.0001
MI OR 2.93 (1.60–2.33), p < 0.0001
AF OR 1.39 (1.65–2.19), p < 0.0001
Corrales-Medina et al. [54] 2012 Overall cardiaccomplications 30-day OR 1.6 (1.04–2.5), p < 0.001
Viasus et al. [55] 2013 Overall cardiaccomplications 30-day OR 2.18 (1.38–3.42)
Aliberti et al. [57] 2015
ACS In-hospital OR 3.57 (1.32–9.69), p = 0.02
Other events OR 2.63 (1.43–4.84), p = NS
Cangemi et al. [58] 2015 Overall cardiaccomplications 6-60 months OR 1.759 (1.099–2.816), p = 0.019
Violi et al. [61] 2017 Overall cardiaccomplications 30-day HR 5.49, p < 0.001
Cilli et al. [63] 2018
Overall cardiac
complications
In-hospital OR 2.18 (1.03–4.61), p = 0.04
90-day NS
ACS: acute coronary syndrome; AF: atrial fibrillation; MI: myocardial infarction; NS: not significant; OR: odds-ratio;
HR: hazard-ratio.
3.4. Long Tterm Outcomes after CAP
Soon after the onset of infection, a plateau of maximum risk for CV events is reached and persists for
the following 30 days [67]. Afterwards, it does not fall abruptly but gradually diminishes, conferring a
long term increased risk that goes well beyond the acute phase [67]. By retrospectively analysing data
from two large observational cohorts of patients without known CV disease, Corrales-Medina et al. have
estimated almost a doubling of CV events during a ten-year period when compared to controls [59].
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3.5. What Is the Role of Pharmacological Therapies?
Multiple investigators aimed to establish a role for CV and immunomodulating drug therapies in
CAP patients. Below, we enumerate pharmacological classes and summarize the available evidence
for their potential use in CAP.
3.5.1. Antiplatelet Drugs
Different receptor pathways serve as potential targets for antiplatelet agents: (1) inhibitors
of thromboxane A2 production (aspirin, triflusal), (2) antagonists of adenosine diphosphate
(ADP)-activated P2Y12 receptors (ticlopidine, clopidogrel, prasugrel, ticagrelor, cangrelor), (3)
antagonists of thrombin-activated proteinase activated receptor 1 (vorapaxar), and (4) GPIIb/IIIa
inhibitors (abciximab, tirofiban, eptifibatide). Conflicting evidence regarding the role of aspirin in
primary prevention led to the publication of two large scale randomized clinical trials who failed to
demonstrate the benefit of aspirin in unselected patients without a previous CV event [68,69]. To make
matters worse, a signal toward increased bleeding was detected, leaving no compelling evidence
for the chronic blocking of platelet cyclooxygenase beyond secondary prevention. In CAP patients,
two prospective propensity matched studies showed that aspirin may be associated with decreased
CV events [70,71]. Recently, ticagrelor, a reversible P2Y12 platelet ADP receptor inhibitor, showed to
decrease leukocyte adherent platelets and inflammatory markers in a small double-blinded trial in
CAP [72]. Patients randomized to ticagrelor had faster amelioration of oxygenation deficit and a trend
towards better progression in lung function test results. Although using an antiplatelet agent in the
acute setting might seem appealing based on heightened inflammation during CAP, this hypothesis
remains to be adequately tested in a powered randomized trial and cannot therefore be recommended.
3.5.2. Statins and Other Lipid Lowering Agents
Impeding cholesterol synthesis is perhaps the most effective drug intervention to reduce the
incidence of de novo and recurring CV events. Data from more that 170,000 patients have demonstrated a
significant impact of statin therapy in all-cause mortality, CV mortality and CV events, with a reassuring
safety profile, in both primary and secondary prevention settings [73]. In vitro and observational
studies led to the belief that reducing inflammation through statins non-lipid lowering effects could
translate into a similar benefit in sepsis, an hypothesis not confirmed in subsequent randomized
trials [74]. Specifically, trials that tested statins in ventilator associated pneumonia [75] or acute
respiratory distress syndrome [76] have not proved to be better than placebo, leaving no convincing
role for their use in this setting. The need for a prolonged exposure to statins in order to obtain clinical
benefit might be an explanation to justify failure to improve outcomes. Recently, two other lipid
lowering drugs (evolocumab, alirocumab) acting through inhibition of PCSK9 (proproteine convertase
subtilisin/kexin type 9, a protein that targets low-density lipoprotein receptors for degradation in the
liver) achieved event reduction on top of statin therapy [77,78]. There are currently no published
human studies exploring a potential effect of this new class of molecules on infection related outcomes.
In an animal model, Berger et al. did not show a reduction of lipopolysaccharide induced mortality
with the administration of anti-PCSK9 antibodies [79].
3.5.3. Beta-Blockers, Angiotensin-Converting Enzyme Inhibitors (ACEi) and Angiotensin Receptor
Blockers (ARB)
Given their established role in CV disease treatment, investigators have explored a possible
benefit of other cardioprotective drugs in CAP patients. Wu et al. employed multilevel regression
modeling to examine the association between CV drug classes and either mortality or CV events [80].
They found that while ACEi and ARBs were associated with decreased mortality, there was no
significant association with decreased CV events. These results suggest that this decreased mortality is
J. Clin. Med. 2020, 9, 414 16 of 23
unlikely due to their potential cardioprotective effects. Higher quality studies are needed to confirm or
refute this unexpected benefit.
3.5.4. Corticosteroids
Corticosteroids have been tested in a wide spectrum of infectious diseases, yielding controversial
results. In CAP, one large patient level meta-analysis [81] pointed to a mortality benefit (34% relative
risk reduction), while in another meta-analysis [82] a very similar absolute reduction reached statistical
significance with one of two random-effects models. In both studies, shorter length of stay (~1 day)
and more hyperglycemic episodes were noted. In the analysis of Briel et al., steroids were associated
with an increased incidence of CAP related readmissions for various reasons including CV events.
Recently, Cangemi et al. found that using corticosteroids for CAP halved the incident of intra-hospital
MI, albeit not reducing either all-cause or CV mortality [83].
3.5.5. Novel Drugs
Canakinumab, a fully human monoclonal antibody targeting 1L-ß interleukin demonstrated a
reduction in recurrent CV events in a randomized clinical trial against placebo [84]. Conversely, the
drug was associated with a small but significant increase of fatal infection or sepsis. Pneumonia rates
were similar in both treatment arms.
3.6. Vaccination
Observational studies and secondary post-hoc analysis of large trials in CV disease have hinted
towards a prognostic impact of influenza and pneumococcal vaccination, particularly in coronary
artery disease related outcomes [85]. In a meta-analysis of five randomized trials, influenza vaccination
was associated with a 36% relative risk reduction in the incidence of major adverse cardiovascular
events during a 12-month period, with no influence in mortality [86]. Patients who had a recent ACS
seemed to derive the largest benefit (55% relative risk reduction). Inferior quality evidence exists
for pneumococcal vaccination. A meta-analysis of observational studies by Ren et al. revealed a
23% reduction in ACS in patients aged 65 or above [87]. The benefit was lost when all patients were
considered and was not extensible to other vascular territories. In the heart failure population, a signal
towards a reduction in a composite endpoint of CV mortality and HF hospitalization in propensity
matched influenza-vaccinated patients from a large trial was identified [88]. There are presently no
studies specifically addressing the effect of pneumococcal immunisation in HF patients.
3.7. Effects of Antibiotics on the Cardiovascular System
While decisive to improve outcomes in patients with CAP, antibiotics are not free from toxicity,
which may include the CV system. Although possessing useful anti-inflammatory properties, macrolides
have been ascribed an increased risk in arrhythmic events and sudden cardiac death (SCD) through
QT interval prolongation and polymorphic ventricular tachycardia facilitation. For azithromycin, the
absolute risk was estimated to be an additional 47 deaths per one million five-day courses of therapy
(all indications considered) when compared to amoxicillin [89]. In a smaller propensity score matching
study, Schembri et al. also found an independent association between clarithromycin use for CAP
and CV events during a one-year follow-up (HR 1.68, 95% CI 1.18–2.38), which was not extensible to
increased mortality [90].
4. Discussion
By analysing epidemiologic data from more than a quarter billion individuals, Collins found
an excess all-cause mortality accompanying a pairwise increase in influenza and pneumonia related
fatalities during successive early 20th century infection outbreaks [91]. After this seminal report, a
burgeoning number of observational studies and reviews has strengthened this association [92–96].
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Our updated systematic review and meta-analysis, encompassing 92,188 patients, the overwhelming
majority (95%) treated as inpatients, further emphasizes the burden of incident CV disease following
CAP. After pooling individual study rates, we found an incidence of overall cardiac complications of
13.9%. The most frequent cardiac complication in inpatients who were not stratified by severity was de
novo or worsening heart failure in 9.2% of patients, 7.2% new-onset or worsening arrhythmias, and
ACS in 4.5%. Stroke was the least common CV event in CAP patients.
The present review accrues data from fourteen more additional studies (~75,000 patients) to the
last review by Corrales-Medina et al. [97], allowing us to perform a supplementary meta-regression
moderated by study year. Globally and individually, the incidence of acute CV events following CAP
seems to be decreasing, albeit slightly. These findings seem to be in line with reported rates of CV
events in the non-CAP population, with the exception of atrial fibrillation. Yearly trends in acute
myocardial infarction show that hospital admission is decreasing in both the US and in Europe [5,98].
This may reflect the improved utilization of protective CV medication in the context of better primary
care based prevention including pneumococcal and influenza immunization, along with improved
secondary prevention after ACS. For heart failure, statistics indicate that the incidence is diminishing, at
the expense of increased prevalence, which can be attributed to demographic shifts, improved quality
of care, medical therapy and handling of comorbidities [99]. Finally, regarding atrial fibrillation, data
published by Schnabel et al. suggest that both its incidence and prevalence are increasing [100]. In our
study, the influence of considering all arrhythmias might have contributed to this apparent discrepancy.
After incorporating more recent studies, the list of independent predictors for cardiac complications
is now longer and more complex. The range of predisposing factors includes host (CV and non-CV
comorbidities) and pathogen-related features. Whilst the baseline comorbidities may share the same
approach and in a way merely denote a sicker patient, different microbes may pose an opportunity
for influencing patient outcomes by improving time to diagnosis and starting pathogen specific
interventions. For pneumococcal pneumonia, bacterial exotoxin pneumolysin has been identified as
key effector of cell and organ damage in murine models [101,102] and could theoretically become
a target for macrolides (or macrolide-like antibiotics), statins or cholesterol rich liposomes [103].
If influenza is being considered, prompt detection may allow the early initiation of neuraminidase
inhibitors. Not surprisingly, if a CV event supervenes after CAP, patients will likely fare worse.
Our aggregated data from eight studies suggests an up to five-fold increase in mortality, mostly for
compiled cardiac complications but also for individual events. Despite its observational nature, this
signal is consistent between studies and possesses biological credibility, anticipating the likely presence
of a true effect.
Notwithstanding the strengths provided by the increased number of studies included and a
clearer view on the temporal trends in CV events after CAP in our updated review and meta-analysis,
some limitations have to be acknowledged. Population heterogeneity, different causal pathogens,
asymmetries in study design and imprecise event definitions may be responsible for the observed
between study variance and wide confidence intervals around the measured effect, reducing the
accuracy estimates of the real effect. Funnel plot analysis is in agreement with such wide dispersion
of data. For heart failure, the interpretation of results is confounded by the fact that both diseases
are simultaneously risk factors and consequences of each other. Finally, we chose not to perform a
meta-regression of stroke due to the paucity of data on acute cerebrovascular events after CAP.
5. Future Directions
Despite the apparent reduction in the event rate, the absolute burden of CV disease means there is
clearly room for improvement. Hence, from a health system perspective, CV morbidity and mortality
after CAP highlight the pressing need for (1) acquiring a better understanding of the pathophysiologic
mediators that lead to acute CV events, (2) conducting well-designed randomized clinical trials to
assess the effect of targeted drug interventions (e.g., statins) on acute CV outcomes in CAP patients,
and (3) implementing a risk stratification model to ameliorate the long-term prognosis of these patients.
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Finally, and despite common features shared by myocardial infarction, heart failure, arrhythmias, and
stroke, gaining deeper insight into the interaction between each event and CAP could prove useful in
tailoring preventative and therapeutic strategies at a patient level.
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